EA201891873A1 - Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r - Google Patents
Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-rInfo
- Publication number
- EA201891873A1 EA201891873A1 EA201891873A EA201891873A EA201891873A1 EA 201891873 A1 EA201891873 A1 EA 201891873A1 EA 201891873 A EA201891873 A EA 201891873A EA 201891873 A EA201891873 A EA 201891873A EA 201891873 A1 EA201891873 A1 EA 201891873A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- crystalline
- pyrrolidin
- biphenyl
- hydroxymethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical class O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100028139 Oxytocin receptor Human genes 0.000 abstract 1
- 101710103206 Oxytocin receptor Proteins 0.000 abstract 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract 1
- 230000032692 embryo implantation Effects 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020076P | 2014-07-02 | 2014-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891873A1 true EA201891873A1 (ru) | 2019-04-30 |
Family
ID=53434312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891873A EA201891873A1 (ru) | 2014-07-02 | 2015-06-10 | Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r |
| EA201790080A EA031353B1 (ru) | 2014-07-02 | 2015-06-10 | Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790080A EA031353B1 (ru) | 2014-07-02 | 2015-06-10 | Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9718772B2 (https=) |
| EP (2) | EP3753921A1 (https=) |
| JP (4) | JP2017519015A (https=) |
| KR (1) | KR102470283B1 (https=) |
| CN (3) | CN106795110A (https=) |
| AU (1) | AU2015283133B2 (https=) |
| CA (1) | CA2953722C (https=) |
| EA (2) | EA201891873A1 (https=) |
| ES (1) | ES2774789T3 (https=) |
| IL (1) | IL249652B (https=) |
| MX (1) | MX371068B (https=) |
| UA (1) | UA122210C2 (https=) |
| WO (1) | WO2016000920A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| CA3009576A1 (en) | 2016-01-04 | 2017-07-13 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| UA127283C2 (uk) * | 2016-07-21 | 2023-07-12 | Обсева С.А. | Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню |
| US20220323410A1 (en) * | 2019-09-03 | 2022-10-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| JP7083793B2 (ja) * | 2019-09-10 | 2022-06-13 | Ｊｆｅケミカル株式会社 | パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法 |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| CA3214150A1 (en) * | 2021-03-31 | 2022-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Formulations for prolonging gestation and for complications of menstruation or gestation |
| WO2026018221A1 (en) * | 2024-07-18 | 2026-01-22 | ReproNovo SA | Crystalline compositions for improving embryo implantation and methods of using the same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU120988A (en) | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| YU183988A (en) | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| US8124124B2 (en) | 1999-12-09 | 2012-02-28 | Reckitt Benckiser Healthcare (Uk) Limited | Compressed tablet formulation comprising non-steroidal anti-inflammatory drugs and methods |
| DE60120661T2 (de) | 2000-03-27 | 2007-07-05 | Applied Research Systems Ars Holding N.V. | Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren |
| DK1268419T3 (da) | 2000-03-27 | 2006-10-02 | Applied Research Systems | Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer |
| TW536751B (en) | 2000-07-14 | 2003-06-11 | Nitto Denko Corp | Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them |
| EP1829861A3 (en) | 2001-03-20 | 2009-01-21 | Laboratoires Serono SA | Pyrrolidine ester derivatives active as oxytocin antagonists |
| KR200245627Y1 (ko) * | 2001-05-15 | 2001-10-15 | 김병두 | 전기 가열부재가 부착된 냄비 |
| KR20040030678A (ko) | 2001-06-18 | 2004-04-09 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 피롤리딘 옥사디아졸 및 티아디아졸 유도체 |
| JP2003192582A (ja) | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) * | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| DE602004024170D1 (de) | 2003-02-27 | 2009-12-31 | Merck Serono Sa Coinsins | Pyrrolidin-derivate als oxytocin antagonisten |
| DE602005003803T2 (de) | 2004-02-26 | 2008-12-24 | Laboratoires Serono S.A., Coinsins | Verfahren zur herstellung von pyrrolidinoximen |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| CA2605923C (en) | 2005-05-10 | 2012-07-24 | Ferring International Center Sa. | Use of antagonists of oxytocin and/or vasopressin |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| EP2205213A2 (en) | 2007-10-01 | 2010-07-14 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| US20160278688A1 (en) | 2012-11-26 | 2016-09-29 | Ferring B.V. | Method and System for Diagnosing Uterine Contraction Levels Using Image Analysis |
| EP2845850A1 (en) * | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| EP3037101B1 (en) | 2014-12-22 | 2019-03-06 | Ferring B.V. | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
-
2015
- 2015-06-10 EP EP19204954.2A patent/EP3753921A1/en active Pending
- 2015-06-10 EP EP15730094.8A patent/EP3164384B1/en active Active
- 2015-06-10 AU AU2015283133A patent/AU2015283133B2/en active Active
- 2015-06-10 JP JP2016573776A patent/JP2017519015A/ja active Pending
- 2015-06-10 CN CN201580047177.XA patent/CN106795110A/zh active Pending
- 2015-06-10 ES ES15730094T patent/ES2774789T3/es active Active
- 2015-06-10 KR KR1020177001267A patent/KR102470283B1/ko active Active
- 2015-06-10 CA CA2953722A patent/CA2953722C/en active Active
- 2015-06-10 UA UAA201700678A patent/UA122210C2/uk unknown
- 2015-06-10 EA EA201891873A patent/EA201891873A1/ru unknown
- 2015-06-10 EA EA201790080A patent/EA031353B1/ru unknown
- 2015-06-10 CN CN202111228955.9A patent/CN114105850A/zh active Pending
- 2015-06-10 MX MX2016016751A patent/MX371068B/es active IP Right Grant
- 2015-06-10 WO PCT/EP2015/062881 patent/WO2016000920A1/en not_active Ceased
- 2015-06-10 CN CN202111229040.XA patent/CN114105851A/zh active Pending
- 2015-06-10 US US14/735,215 patent/US9718772B2/en active Active
-
2016
- 2016-12-19 IL IL249652A patent/IL249652B/en unknown
-
2017
- 2017-05-25 US US15/604,816 patent/US10752583B2/en active Active
-
2020
- 2020-11-09 JP JP2020186785A patent/JP2021038236A/ja active Pending
-
2022
- 2022-11-18 JP JP2022184804A patent/JP2023018037A/ja active Pending
-
2024
- 2024-10-18 JP JP2024182585A patent/JP2025013885A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170320822A1 (en) | 2017-11-09 |
| JP2025013885A (ja) | 2025-01-28 |
| CN114105851A (zh) | 2022-03-01 |
| AU2015283133B2 (en) | 2019-05-16 |
| ES2774789T3 (es) | 2020-07-22 |
| EP3164384B1 (en) | 2019-12-04 |
| MX371068B (es) | 2020-01-15 |
| EP3753921A1 (en) | 2020-12-23 |
| US10752583B2 (en) | 2020-08-25 |
| WO2016000920A1 (en) | 2016-01-07 |
| CN106795110A (zh) | 2017-05-31 |
| EA031353B1 (ru) | 2018-12-28 |
| JP2021038236A (ja) | 2021-03-11 |
| US20160002160A1 (en) | 2016-01-07 |
| CA2953722A1 (en) | 2016-01-07 |
| JP2023018037A (ja) | 2023-02-07 |
| JP2017519015A (ja) | 2017-07-13 |
| IL249652B (en) | 2021-09-30 |
| AU2015283133A1 (en) | 2017-02-16 |
| KR102470283B1 (ko) | 2022-11-23 |
| KR20170023961A (ko) | 2017-03-06 |
| EA201790080A1 (ru) | 2017-06-30 |
| US9718772B2 (en) | 2017-08-01 |
| UA122210C2 (uk) | 2020-10-12 |
| CN114105850A (zh) | 2022-03-01 |
| EP3164384A1 (en) | 2017-05-10 |
| MX2016016751A (es) | 2017-08-08 |
| IL249652A0 (en) | 2017-02-28 |
| CA2953722C (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790080A1 (ru) | Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r | |
| EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
| JOP20210109B1 (ar) | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| MX373363B (es) | Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina. | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA202190485A1 (ru) | Соединения, модулирующие fxr (nr1h4) | |
| EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| EA201790384A1 (ru) | Полиморфы селинексора | |
| EA201691730A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения опосредованных комплементом расстройств | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| MX363697B (es) | Formulaciones orales de derivados de pirrolidina. | |
| EA201591512A1 (ru) | Борсодержащие молекулы, способы и составы | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CO2018005983A2 (es) | Compuestos de isoindol | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA201790905A1 (ru) | Способ лечения состояний, связанных с рецептором pgi2 | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2022000746A (es) | Dimetilfumarato y regimenes de vacunacion. | |
| EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. |